QFA
RETA

Quattro Financial Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Quattro Financial Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$496K – 122
2021
Q3 		$496K Hold
5,000
– – 0.13% 77
2021
Q2 		$651K Hold
5,000
– – 0.17% 73
2021
Q1 		$452K Buy
+5,000
New +$583K 0.1% 84

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Quattro Financial Advisors's RETA Position: Q4 2021 in Review

Quattro Financial Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 5,000 shares — an estimated $496K sold.

Quattro Financial Advisors first reported a position in RETA in Q1 2021 and held it in 3 quarters. The position peaked at $651K in Q2 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Quattro Financial Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Quattro Financial Advisors sold 5,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $496K.
  • Quattro Financial Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
  • Quattro Financial Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $651K in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Quattro Financial Advisors's 13F filing for Q4 2021, filed 27 Jan 2022.